Rocket Companies Inc. Class A Common Stock vs Revvity Inc — how do they compare? Rocket Companies Inc. Class A Common Stock trades at $10.55 (market cap $30.67B), while Revvity Inc trades at $151.84 (market cap $17.30B). The key difference: Rocket Companies Inc. Class A Common Stock is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Rocket Companies Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Companies Inc. Class A Common Stock for 0 Days and Revvity Inc for 13 Days on average.
| RKT | RVTY | |
|---|---|---|
Market Cap | $30.67B | $17.30B |
Volume | 41,104,143 | 1,387,588 |
Sector | Financials | Health |
52-Week High | $23.44 | $157.36 |
52-Week Low | $10.53 | $82.26 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $60.66B | $19.62B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →